|
1
|
Zhao Z, Liao H and Ju Y: Effect of
compound Kushen injection on T-cell subgroups and natural killer
cells in patients with locally advanced non-small-cell lung cancer
treated with concomitant radiochemotherapy. J Tradit Chin Med.
36:14–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Videtic GM, Hu C, Singh AK, Chang JY,
Parker W, Olivier KR, Schild SE, Komaki R, Urbanic JJ and Choy H: A
randomized phase 2 study comparing 2 stereotactic body radiation
therapy schedules for medically inoperable patients with stage I
peripheral non-small cell lung cancer: NRG oncology RTOG 0915
(NCCTG N0927). Int J Radiat Oncol Biol Phys. 93:757–764. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zinner RG, Obasaju CK, Spigel DR, Weaver
RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos
PG, Liu J, et al: PRONOUNCE: Randomized, open-label, phase III
study of first-line pemetrexed + carboplatin followed by
maintenance pemetrexed versus paclitaxel + carboplatin +
bevacizumab followed by maintenance bevacizumab in patients ith
advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol.
10:134–142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Semrau S, Zettl H, Hildebrandt G, Klautke
G and Fietkau R: Older patients with inoperable non-small cell lung
cancer: Long-term survival after concurrent chemoradiotherapy.
Strahlenther Onkol. 190:1125–1132. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu W and Zhang Z: A phase II clinical
study of using nab-paclitaxel as second-line chemotherapy for
Chinese patients with advanced non-small cell lung cancer. Med
Oncol. 32:4982015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McKenna E, Traganos F, Zhao H and
Darzynkiewicz Z: Persistent DNA damage caused by low levels of
mitomycin C induces irreversible cell senescence. Cell Cycle.
11:3132–3140. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Y, Qi K, Zu L, Wang M, Wang Y and Zhou
Q: Anti-apoptotic brain and reproductive organ-expressed proteins
enhance cisplatin resistance in lung cancer cells via the protein
kinase B signaling pathway. Thorac Cancer. 7:190–198. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reck M, Paz-Ares LG, de Marinis F,
Molinier O, Sahoo TP, Laack E, John W, Zimmermann AH, Visseren-Grul
C and Gridelli C: PARAMOUNT: Descriptive subgroup analyses of final
overall survival for the phase III study of maintenance pemetrexed
versus placebo following induction treatment with pemetrexed plus
cisplatin for advanced nonsquamous non-small-cell lung cancer. J
Thorac Oncol. 9:205–213. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang L, Yuan Y, Fu C, Xu X, Zhou J, Wang
S, Kong L, Li Z, Guo Q and Wei L: LZ-106, a novel analog of
enoxacin, inducing apoptosis via activation of ROS-dependent DNA
damage response in NSCLCs. Free Radic Biol Med. 95:155–168. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Petrelli F and Barni S: Non-cancer-related
mortality after cisplatin-based adjuvant chemotherapy for non-small
cell lung cancer: A study-level meta-analysis of 16 randomized
trials. Med Oncol. 30:6412013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Niho S, Kenmotsu H, Sekine I, Ishii G,
Ishikawa Y, Noguchi M, Oshita F, Watanabe S, Nakajima R, Tada H and
Nagai K: Combination chemotherapy with irinotecan and cisplatin for
large-cell neuroendocrine carcinoma of the lung: A multicenter
phase II study. J Thorac Oncol. 8:980–984. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Q, Yang Z, Chen M and Liu Y:
Downregulation of microRNA-196a enhances the sensitivity of
non-small cell lung cancer cells to cisplatin treatment. Int J Mol
Med. 37:1067–1074. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu L, Pu X, Wang Q, Cao J, Xu F, Xu LI and
Li K: miR-96 induces cisplatin chemoresistance in non-small cell
lung cancer cells by downregulating SAMD9. Oncol Lett. 11:945–952.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Z, Zhang L, Yin ZY, Fan XL, Hu B,
Wang LQ and Zhang D: miR-107 regulates cisplatin chemosensitivity
of A549 non small cell lung cancer cell line by targeting cyclin
dependent kinase 8. Int J Clin Exp Pathol. 7:7236–7241.
2014.PubMed/NCBI
|
|
15
|
Berghmans T, Ameye L, Lafitte JJ, Colinet
B, Cortot A, CsToth I, Holbrechts S, Lecomte J, Mascaux C, Meert
AP, et al: Prospective validation obtained in a similar group of
patients and with similar high throughput biological tests failed
to confirm signatures for prediction of response to chemotherapy
and survival in advanced NSCLC: A prospective study from the
european lung cancer working party. Front Oncol. 4:3862015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu W, Jin P and Liu W: Periostin
contributes to cisplatin resistance in human non-small cell lung
cancer A549 cells via activation of Stat3 and Akt and upregulation
of survivin. Cell Physiol Biochem. 38:1199–1208. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu HH, Wu JY, Cheng YW, Chen CY, Lee MC,
Goan YG and Lee H: cIAP2 upregulated by E6 oncoprotein via
epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT
pathway confers resistance to cisplatin in human papillomavirus
16/18-infected lung cancer. Clin Cancer Res. 16:5200–5210. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu B, Zhang Y, Jia L, Wu H, Fan C, Sun Y,
Ye C, Liao M and Zhou J: Binding of the pathogen receptor HSP90AA1
to avibirnavirus VP2 induces autophagy by inactivating the AKT-MTOR
pathway. Autophagy. 11:503–515. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sebastian M, Papachristofilou A, Weiss C,
Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B,
et al: Phase Ib study evaluating a self-adjuvanted mRNA cancer
vaccine (RNActive®) combined with local radiation as
consolidation and maintenance treatment for patients with stage IV
non-small cell lung cancer. BMC Cancer. 14:7482014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Neault M, Mallette FA and Richard S:
miR-137 modulates a tumor suppressor Network-inducing senescence in
pancreatic cancer cells. Cell Rep. 14:1966–1978. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shin KK, Kim YS, Kim JY, Bae YC and Jung
JS: miR-137 controls proliferation and differentiation of human
adipose tissue stromal cells. Cell Physiol Biochem. 33:758–768.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen B, Wang X, Zhao W and Wu J: Klotho
inhibits growth and promotes apoptosis in human lung cancer cell
line A549. J Exp Clin Cancer Res. 29:992010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fang C, Zhang J, Qi D, Fan X, Luo J, Liu L
and Tan Q: Evodiamine induces G2/M arrest and apoptosis via
mitochondrial and endoplasmic reticulum pathways in H446 and H1688
human small-cell lung cancer cells. PLoS One. 9:e1152042014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chougule M, Patel AR, Sachdeva P, Jackson
T and Singh M: Anticancer activity of Noscapine, an opioid alkaloid
in combination with Cisplatin in human non-small cell lung cancer.
Lung Cancer. 71:271–282. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Peng Y, Wang L, Qing Y, Li C, Ren T, Li Q,
Li M, Zhang S, Shan J, Wang G, et al: Polymorphisms of BCL2 and BAX
Genes associate with outcomes in advanced Non-small cell lung
cancer patients treated with platinum-based Chemotherapy. Sci Rep.
5:177662015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Żuryń A, Litwiniec A, Safiejko-Mroczka B,
Klimaszewska-Wiśniewska A, Gagat M, Krajewski A, Gackowska L and
Grzanka D: The effect of sulforaphane on the cell cycle, apoptosis
and expression of cyclin D1 and p21 in the A549 non-small cell lung
cancer cell line. Int J Oncol. 48:2521–2533. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Y, Cao Y, Yang D, Li K, Wang Z, Zhu
J, Bunjhoo H, Xiong S, Xu Y and Xiong W: Increase of the
therapeutic effect on non-small-cell lung cancer cells with
combination treatment of shRNA against Cyclin D1 and Bcl-xL in
vitro. Exp Ther Med. 3:255–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Singh T, Prasad R and Katiyar SK:
Inhibition of class I histone deacetylases in non-small cell lung
cancer by honokiol leads to suppression of cancer cell growth and
induction of cell death in vitro and in vivo. Epigenetics. 8:54–65.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, Dong
SW, Li RL, Zhao MY, Zhen Y, Yu XL, et al: Alpha-enolase promotes
cell glycolysis, growth, migration, and invasion in non-small cell
lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol.
8:222015. View Article : Google Scholar : PubMed/NCBI
|
